II. Indication

  1. Genital Wart
  2. Recalcitrant Common Warts (not FDA approved)
  3. Molluscum Contagiosum (not FDA approved)

III. Contraindications

  1. Do not use on mucous membranes

IV. Precautions

  1. Weakens Condoms and diaphragms
  2. Avoid sexual contact when cream is on skin

V. Dosing

  1. General
    1. Apply thin layer to external visible lesions
    2. Rub in cream until it disappears
    3. Wash off with soap and water in 6-10 hours
  2. Genital Warts
    1. Apply 5% cream to affected area qhs for 3 nights/week
    2. Apply at bedtime and wash off in 6-10 hours
    3. May repeat weekly cycles for up to 16 weeks
  3. Recalcitrant warts
    1. Apply 3 times per week for a maximum of 16 weeks
    2. Apparently very effective if extensive involvement
  4. Molloscum contagiosum
    1. Apply to skin lesion for 6-10 hours, then wash off
    2. Apply 3 times weekly for 4 to 16 weeks

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Cost: Medications

imiquimod (on 8/17/2016 at Medicaid.Gov Survey of pharmacy drug pricing)
IMIQUIMOD 5% CREAM PACKET Generic $3.39 each
aldara (on 8/17/2016 at Medicaid.Gov Survey of pharmacy drug pricing)
ALDARA 5% CREAM Generic $10.28 each

Ontology: imiquimod (C0165032)

Definition (NCI_NCI-GLOSS) A drug used to treat early basal cell skin cancer and certain other skin conditions. It is being studied in the treatment of other types of cancer. Imiquimod is a type of biological response modifier.
Definition (NCI) A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. (NCI04)
Definition (PDQ) A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38558&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38558&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1431" NCI Thesaurus)
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C056493
SnomedCT 108939005, 386941002
English 1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine, 1H-Imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)-, imiquimod, 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline, IMQ, imiquimod (medication), wart therapeutic agents imiquimod, imiquimod [Chemical/Ingredient], IMIQUIMOD, Imiquimod, Imiquimod (product), Imiquimod (substance)
Spanish imiquimod (producto), imiquimod (sustancia), imiquimod

Ontology: Aldara (C0718327)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C056493
English aldara, 3M Brand of Imiquimod, Aldara